CIK 0001874252
- Emerging growth company
Quantum Cyber N.V.
Sign in to watch- Ticker
- QUCY
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Netherlands
- Entity type
- Operating
- Phone
- +49 61315542860
- Business address
- ROBERT KOCH STRASSE 50, MAINZ, Germany
- Former names
- MAINZ BIOMED N.V., Mainz Biomed B.V.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-11 | Caragol William J Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +212,500 | 212,500 | ||
| 2026-08-05 | Lazar David E. Chief Executive Officer | Conversion | +9,000,000 | $9.00 | $81.0M | 9,000,000 |
| 2026-08-05 | Lazar David E. Chief Executive Officer | Conversion | +9,000,000 | $9.00 | $81.0M | 18,000,000 |
| 2026-08-05 | Lazar David E. Chief Executive Officer | Conversion | +9,000,000 | $9.00 | $81.0M | 27,000,000 |
| 2026-08-05 | Lazar David E. Chief Executive Officer | Conversion | +28,057,500 | $225.00 | $6.3B | 55,057,500 |
| 2026-08-05 | Lazar David E. Chief Executive Officer | Conversion · Series A Preferred Shares | −1,000,000 | 0 | ||
| 2026-08-05 | Lazar David E. Chief Executive Officer | Conversion · Series B Preferred Shares | −1,000,000 | 0 | ||
| 2026-08-05 | Lazar David E. Chief Executive Officer | Conversion · Series C Preferred Shares | −1,000,000 | 0 | ||
| 2026-08-05 | Lazar David E. Chief Executive Officer | Conversion · Series D Preferred Shares | −124,700 | 875,300 | ||
| 2026-07-31 | Ben-Tzvi Avraham Director | Grant or award | +112,259 | 251,400 | ||
| 2026-07-31 | O'Rourke Peter Director | Grant or award · Stock Option (Right to Buy) | +190,840 | 190,840 | ||
| 2026-07-31 | NATAN DAVID Director | Grant or award · Stock Option (Right to Buy) | +190,840 | 190,840 | ||
| 2026-07-31 | Caragol William J Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +212,500 | 212,500 | ||
| 2026-07-31 | Buffalino Louis R. Director | Grant or award · Stock Option (Right to Buy) | +425,000 | 425,000 | ||
| 2026-07-22 | O'Rourke Peter Director | Grant or award · Stock Option (Right to Buy) | +191,860 | 191,860 | ||
| 2026-07-22 | NATAN DAVID Director | Grant or award · Stock Option (Right to Buy) | +191,860 | 191,860 | ||
| 2026-07-22 | Caragol William J Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +212,500 | 212,500 | ||
| 2026-07-22 | Buffalino Louis R. Director | Grant or award · Stock Option (Right to Buy) | +425,000 | 425,000 | ||
| 2026-07-22 | Ben-Tzvi Avraham Director | Grant or award | +112,859 | 252,000 | ||
| 2026-07-06 | O'Rourke Peter Director | Grant or award · Stock Option (Right to Buy) | +112,859 | 112,859 |
Page 1 of 2 · 33 trades